---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-24-000015"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:35:14.175721+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tarsus Q4 XDEMVY sales $13.1M; positive Phase 2a rosacea data

## Summary
- XDEMVY net product sales $13.1M in Q4, $14.7M total since late-August launch; >17,400 bottles dispensed.
- Positive Phase 2a Galatea trial for TP-04 in papulopustular rosacea: statistically significant improvements in lesions and IGA score vs vehicle at Week 12.
- Q4 net loss $41.9M ($1.31 EPS); full-year net loss $135.9M ($4.62 EPS).
- Cash, equivalents and marketable securities $227.4M as of Dec 31, 2023.
- ~6,000 ECPs have started patients on XDEMVY; >50% prescribed to multiple patients as of Feb 23.

## SEC filing metadata
- accession: 0001819790-24-000015
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979024000015/0001819790-24-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979024000015/tars-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-24-000015
- JSON: https://secwatch.observer/filing/0001819790-24-000015.json
- Plain text: https://secwatch.observer/filing/0001819790-24-000015.txt

## Key facts
- Earnings Releases
  Tarsus Pharmaceuticals, Inc. reported Full Year 2023 results: revenue $17.4 million.
  - Period: Full Year 2023
  - Revenue: $17.4 million
  - Result: reported results
  source text: Total revenues were $17.4 million, driven primarily by $14.7 million in XDEMVY net product sales, representing approximately four months of sales following the launch in late August.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979024000015/0001819790-24-000015-index.htm
- Earnings Releases
  Tarsus Pharmaceuticals, Inc. reported Fourth Quarter 2023 results: revenue $13.1 million, net income $(41.9 million), EPS $(1.31).
  - Period: Fourth Quarter 2023
  - Revenue: $13.1 million
  - Net income: $(41.9 million)
  - EPS: $(1.31)
  - Result: reported results
  source text: Recent Business Achievements Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and generated fourth quarter net product sales of $13.1 million, and $14.7 million in the first four months since launch Delivered more than 17,400 bottles of XDEMVY to patients Continued pipeline execution – reported positive
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979024000015/0001819790-24-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.